BioCryst Pharmaceuticals | BCRX - 股票



金融业
股票价格
USD
资产
USD 465.05M
现金及等价物
USD 171.59M
销售成本
USD 9.52M
流动资产
USD 373.63M
流动负债
USD 195.39M
债务
USD 828.6M
股息收益率
0
EBIT
USD 260.39M
EBITDA
USD 51.7M
员工
536
EPS每股收益
USD 1.17
股本和储备
USD -553.84M
销售毛利
USD 153.05M
债务利息支出
USD 14.14M
利息收入
USD -0.13
贷款资金
USD 395.2M
市值
USD 1.8B
净收入
USD 245.85M
营业费用
USD -553.84M
营业利润
USD 260.39M
普通股股本
USD 213.06M
PE价格收益
6.06
税前利润
USD 248.02M
销售收入
USD 406.56M
销售和管理费用
USD 95.78M
股票
USD 5.99M
贸易债权人
USD 10.96M
应收帐款人
USD 106.82M


股票 更改 日
Alnylam Pharmaceuticals USD 200.15M 117.43M 2026-03
BioCryst Pharmaceuticals USD 5.98M 587K 2026-03
Chugai Pharma JPY 276.85B 30.52B 2025-12
Daiichi Sankyo JPY 608.55B 93.64B 2025-09
Gilead Sciences USD 1.91B 140M 2026-03
GlaxoSmithKline GBP 6.16B 233M 2026-03
Glaxosmithkline GBP 6.12B 46M 2025-09
Incyte USD 115.62M 14.56M 2026-03
Ionis Pharmaceuticals USD 5.56M 4.49M 2026-03
Karyopharm Therapeutics USD 4.04M 72K 2025-12
Neurocrine Biosciences USD 64.5M 4.5M 2026-03
Novavax USD 11.46M 87K 2026-03
PTC Therapeutics USD 75.57M 4.08M 2026-03
Regeneron Pharmaceuticals USD 3.1B 97.2M 2026-03
Roche Holding CHF 7.6B 9M 2025-06
Sarepta Therapeutics USD 1B 86.37M 2026-03
Ultragenyx Pharmaceutical USD 55M 3M 2026-03
Vertex Pharmaceuticals USD 1.77B 79.9M 2026-03